By examining genome-wide enhancer methylation levels in the prefrontal cortex of AD patients, Li et al. identify 1,224 enhancer regions methylated differentially and most of their methylation levels are decreased in AD neurons, which are associated with Aβ, tau, and cognitive impairment (65). The gene discussed is MAPT; the disease is Alzheimer disease.